Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This is a dose escalation study that will assess the safety of Vorinostat, a Histone
Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with
advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Vorinostat has been approved for
use in patients with cutaneous T-cell lymphomas, but several pre-clinical studies suggest
activity in lung cancer cell lines. Several HDAC inhibitors,including Vorinostat, may enhance
the effect of radiotherapy, and this study will seek to confirm this.